Celina Nadelman, MD
Cytopathology · Los Angeles, CANPI 1437259595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Merck at 27.2% of the total. Reporting peaked in 2024 at $246 and has fallen 88.9% since, to $27 in 2025.
Across 18 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$118
- Daiichi Sankyo Inc.$81
- AstraZeneca$65
- Sanofi$58
- Genentech USA, Inc.$47
- AbbVie$25
- plus $42 from 2 others
What the payments were for
- Food & beverage$435100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $118 |
| Daiichi Sankyo Inc. | 3 | $81 |
| AstraZeneca | 3 | $65 |
| Sanofi | 2 | $58 |
| Genentech USA, Inc. | 2 | $47 |
| AbbVie | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Pfizer | 1 | $18 |
How this compares
$435 in reported general payments places this provider in the 75th percentile of 26 cytopathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cytopathology in Los Angeles
- William TempleLos Angeles$125
- Neda MoatamedLos Angeles$36
- Teresa DarraghSan Francisco$20K
- Thomas CooperWestminster$4K
- Sue ChangDuarte$4K
- Natalie MillsArcadia$1K
- David HewittVisalia$586
- Rose VenegasTorrance$552
- David LieuLos Alamitos$359
- Sepi MahootiSan Diego$215
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.